Chemokines and T lymphocyte activation: II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice

J Immunol. 1996 Mar 15;156(6):2104-11.

Abstract

Previous studies from this laboratory have demonstrated that the chemokines RANTES (recombinant human regulated upon activation, normally T cell expressed and presumably secreted), macrophage chemotactic peptide-1, recombinant human macrophage inflammatory protein-1 alpha (rhMIP-1 alpha) IL-8, and IP-10 are capable of inducing human T cell infiltration into the injection site of severe combined immunodeficiency (SCID) mice reconstituted with human PBL. However, the ability of these chemokines to facilitate T cell homing into various lymphoid tissues has not been examined. Initial studies focused on the ability of rhMIP-1 beta to induce human T cell infiltration into injection sites in human PBL-SCID mice. SCID mice received s.c. injections of rhMIP-1 beta or PBS (1 microgram/injection) in the hindflank for 4 h or sequential injections for 3 days. Biopsies of the MIP-1 beta injection site revealed the presence of significant mononuclear cell accumulation 72 h after injection. Immunohistologic evaluation determined that significant numbers of human CD3+ T cells were recruited in response to MIP-1 beta injections, and this infiltration could be specifically blocked by co-administration of anti-MIP-1 beta antiserum. We subsequently examined these chemokine-injected mice for the effect of trafficking of human T cells to peripheral lymphoid organs. Flow cytometric analysis of the thymus in human PBL-SCID mice revealed that treatment with rhMIP-1 beta or rhRANTES, but not platelet factor-4, resulted in improved thymic homing of the human T cells after 72 h. This trafficking effect was shown to be direct, as pretreatment of the human T cells with the chemokines in vitro also improved peripheral lymphoid trafficking of the human cells. In addition, co-injection of rhMIP-1 beta with anti-1 beta antiserum abrogated the increase in T cell homing to the thymus. These data demonstrate that MIP-1 beta and RANTES directly augment human T cell trafficking to peripheral murine lymphoid tissues. Chemokines may, therefore, under either isogeneic or xenogeneic conditions, play a role in normal lymphocyte recirculation and homing, and may be of potential clinical use in promoting immune cell trafficking and function.

MeSH terms

  • Animals
  • Cell Movement / drug effects
  • Cell Movement / immunology*
  • Chemokine CCL4
  • Chemokine CCL5 / administration & dosage
  • Chemokine CCL5 / immunology
  • Chemokine CCL5 / pharmacology
  • Chemokines / administration & dosage
  • Chemokines / immunology
  • Chemokines / pharmacology*
  • Humans
  • Injections, Subcutaneous
  • Lymphocyte Activation / drug effects*
  • Macrophage Inflammatory Proteins
  • Mice
  • Mice, SCID
  • Monokines / administration & dosage
  • Monokines / immunology
  • Monokines / pharmacology
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / immunology
  • Recombinant Proteins / pharmacology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology
  • Thymus Gland / cytology
  • Thymus Gland / drug effects
  • Thymus Gland / immunology

Substances

  • Chemokine CCL4
  • Chemokine CCL5
  • Chemokines
  • Macrophage Inflammatory Proteins
  • Monokines
  • Recombinant Proteins